Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Washington Roundup

Executive Summary

The latest medical device regulatory and reimbursement news from Elsevier Business Intelligence's "The Gray Sheet."

You may also be interested in...



Total Joint Market: Slowly Recovering

The $13 billion total joint market is facing a number of challenges coming off the recent recession. Although the demographics related to joint replacement remain strong, manufacturers continue to be plagued by downward pressure on implant prices, a slowdown in procedure volumes, and an ongoing shift in hospital purchasing. Many believe that J&J's recent acquisition of Synthes will spark a wave of consolidation in the industry.

FDA Panel Will Have To Weigh Pediatric Cancer Drug’s ‘Higher Level’ Of Uncertainty Against Rare, Devastating Disease

US WorldMeds NDA package for eflornithine for high-risk neuroblastoma provides “a higher level of uncertainty than is typically seen in oncology applications,” agency says. Though FDA seems largely satisfied with the sponsor’s externally controlled study, confirmatory evidence may be lacking. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035435

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel